Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001333 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of Intrathecal Topotecan
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00001333: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00001333 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001333, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the qualitative and quantitative toxicity of intrathecal topotecan, a topoisomerase I inhibitor, in patients with meningeal malignancies refractory to conventional therapy (radiation therapy and chemotherapy).
Interventions
- DRUG topotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1993-02 |
| Est. Completion | 2000-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001333
The ClinicalTrials.gov registry entry for NCT00001333 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which topotecan is the first listed.
NCT00001333 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001333 about?
NCT00001333 is a clinical study titled "Phase I Study of Intrathecal Topotecan". The purpose of this study is to determine the qualitative and quantitative toxicity of intrathecal topotecan, a topoisomerase I inhibitor, in patients with meningeal malignancies refractory to conventional therapy (radiation therapy and chemotherapy).
What is the current status of trial NCT00001333?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 1993-02. Estimated completion is 2000-12.
What interventions are being tested in trial NCT00001333?
The interventions under investigation include: topotecan (DRUG).
Who is sponsoring clinical trial NCT00001333?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.